Trials / Completed

CompletedNCT04844125

SHR - 1209 Treatment Efficacy and Safety of the Patients With Hypercholesterolemia Ⅲ Period Clinical Research

A Multicentric, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of SHR-1209 in Patients With Hypercholesterolemia

Status: Completed
Phase: Phase 3
Study type: Interventional
Enrollment: 144 (actual)

Sponsor: Jiangsu HengRui Medicine Co., Ltd. · Industry
Sex: All
Age: 18 Years – 80 Years
Healthy volunteers: Not accepted

Summary

This study is ongoing to evaluate the efficacy and safety of SHR-1209 in patients with hypercholesterolemia.

Conditions

Primary Hypercholesterolemia

Interventions

Type	Name	Description
DRUG	SHR-1209	SHR-1209
DRUG	SHR-1209 Placebo	SHR-1209 Placebo

Timeline

Start date: 2021-04-14
Primary completion: 2022-08-12
Completion: 2022-08-12
First posted: 2021-04-14
Last updated: 2023-04-25

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT04844125. Inclusion in this directory is not an endorsement.